Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis.
Med Hypotheses
; 146: 110365, 2021 Jan.
Article
in English
| MEDLINE | ID: covidwho-939146
ABSTRACT
Immunotherapy is the newest approach to combat cancer. It can be achieved using several strategies, among which is the dendritic cell (DC) vaccine therapy. Several clinical trials are ongoing using DC vaccine therapy either as a sole agent or in combination with other interventions to tackle different types of cancer. Immunotherapy can offer a potential treatment to coronavirus disease 2019 (COVID-19) the worst pandemic facing this generation, a disease with deleterious effects on the health and economic systems worldwide. We hypothesize that DC vaccine therapy may provide a potential treatment strategy to help combat COVID-19. Cancer patients are at the top of the vulnerable population owing to their immune-compromised status. In this review, we discuss DC vaccine therapy in the light of the body's immunity, cancer, and newly emerging infections such as COVID-19 in hopes of better-customized treatment options for patients with multiple comorbidities.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Dendritic Cells
/
Models, Immunological
/
COVID-19
/
Immunotherapy
/
Neoplasms
Type of study:
Prognostic study
/
Randomized controlled trials
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Med Hypotheses
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS